Innovation of constant values

dedicated to developing and manufacturing the best synthetic recombinant human collagen products

Jiangsu Trautec Medical Technology (Trautec), founded in 2015, is dedicated with a mission of researching and developing synthetic recombinant human collagen (SRHC) biomaterials.

Trautec has over 17 million dollars invested in research and development (R&D) of synthetic recombinant human collagen (SRHC) production based on biomaterials. The 100,000 square feet production facility is based in Jiangsu, and its U.S. branch is headquartered in Ontario, California. The company will continue to expand the application of SRHC products in high-end fields such as medicine, medical regeneration and medical aesthetics, and occupy the forefront of the industry, aiming to build a global leading company in synthetic recombinant human collagen products.



  • Founded in Jiangsu, China


  • Introduced synthetic recombinant human collagen (SRHC)


  • Established R&D team
  • Begin production trials of SRHC


  • Reached 20 tons of fermentation standardized production of SRHC
  • World’s first clinical trial of SRHC of skin burns treatments


  • Completed the pilot test of SRHC Type I and Type III


  • Completed the pilot test of SRHC Type XVII
  • Launched the clinical trial of SRHC implant
  • Clinical study featured on ScienceDirect publication BURNS
  • Awarded Jiangsu province “Little Giant” enterprise


  • Established U.S. branch in Ontario, California
  • Launched clinical trial of SRHC implant
  • Shiseido Beauty Innovations Fund announces investment in Trautec as lead investor
  • SRHC Type XVII awarded PCHi 2022 Fountain Awards in raw material innovation
  • SRHC Type XVII awarded Ringier Technology Innovation Awards 2022 in personal care
  • ISO14004 Certification
Intellectual property

Patents and Certifications

  • 1 PCT application
  • 9 authorized inventions
  • 12 invention applications
  • 29 utility model patents
  • 36 product registration certificates
  • 56 registration certificates in process
  • 7 Class III medical devices in process